Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a potential treatment for diabetic macular edema …
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial Read More
COATESVILLE, PA — The Alliance for Health Equity (AHE) has announced that Union Community Care has been chosen as the Federally Qualified Health Center (FQHC) for the Brandywine Center, located …
Union Community Care Transforms Coatesville Healthcare—A Bold Step Toward Equity and Access Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for OCU400, a groundbreaking gene therapy targeting retinitis pigmentosa …
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa Read More
HARRISBURG, PA — A groundbreaking step toward transforming behavioral health care in Pennsylvania has taken root in Harrisburg. The Shapiro Administration, continuing its commitment to improving access to mental health and …
New Crisis Center in Harrisburg: Could It Change Mental Health Care for Thousands? Read More
WASHINGTON, D.C. — The Centers for Disease Control and Prevention (CDC), alongside the U.S. Department of Agriculture (USDA) and the Department of the Interior (DOI), has released the country’s first National …
U.S. Agencies Unveil National One Health Framework to Combat Zoonotic Diseases Read More
WASHINGTON, D.C. — The Centers for Disease Control and Prevention (CDC) recently confirmed the first death in the United States linked to H5N1 bird flu. The patient, who was from …
First U.S. H5 Bird Flu Death Confirmed—What the CDC Wants You to Know About Your Risk Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations …
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease Read More
BERWYN, PA — AscellaHealth has unveiled its Specialty & Rare Pipeline Digest™, a comprehensive digital resource aimed at providing critical information on specialty and rare disease drug launches, biosimilars, and cell …
AscellaHealth Introduces Specialty & Rare Pipeline Digest to Advance Healthcare Insights Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that the first group of patients has been dosed in a pivotal Phase 2 clinical trial evaluating its QTORIN™ 3.9% rapamycin …
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD) …
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study Read More